BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Beactica and Almac Discovery Announce Their First Fragment-Based Drug Discovery Agreement


12/6/2011 11:15:38 AM

UPPSALA, Sweden, December 6, 2011 /PRNewswire/ --

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.

"We are proud that Almac Discovery has selected Beactica's platform to identify high-quality medicinal chemistry starting points for a number of their prioritised programmes" said Beactica's CEO, Dr Per Källblad. "Our team looks forward to supporting them in their discovery of novel and innovative treatments for cancer".

Prof Tim Harrison, VP Medicinal Chemistry at Almac Discovery, said: "By collaborating with first-class companies, Almac Discovery utilises strategic outsourcing to complement in-house expertise. We have been impressed with Beactica's expertise and capabilities in SPR biosensor-based drug discovery and are looking forward to a fruitful collaboration on these important targets. We plan to take projects to clinical proof of concept (or earlier) before out-licensing or partnering for further development".

Financial terms of the agreement were not disclosed.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The company has its headquarter in Uppsala, Sweden. For more information, visit http://www.beactica.com.

About Almac Discovery

Almac Discovery is an independent member of the Almac Group. The company is focused on the discovery and development of novel and innovative approaches to the treatment of cancer and associated conditions, with the goal of developing biomarkers or diagnostic tools in parallel with each potential new therapeutic. Founded in 2008, Almac Discovery is located in Craigavon, Northern Ireland. For more information, visit http://www.almacgroup.com/discovery/.


SOURCE Beactica AB


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->